All News
NOBILITY: a Trial of Obinutuzumab in Proliferative Lupus Nephritis
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
Read Article
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).
Read Article
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
https://t.co/ibavOjmBJd https://t.co/DseCTMRX7J
Links:
Dr. John Cush RheumNow ( View Tweet)
PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 14.9% UST vs 19.2% TNFk and Minimal Dz Activity was 26.4% UST vs 30.8% TNFi at 6 months - both were equipotent in PsA https://t.co/RLadZa6YTI https://t.co/I7eKxD3XyI
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download wherever you get your podcasts!
https://t.co/Y6Pqko1tYm https://t.co/6RU1nuj7QU
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU
Links:
Dr. John Cush RheumNow ( View Tweet)
Kikuchi’s Dz (AKA Kikuchi-Fujimoto dz) is rare, affects young women >men w/ recurrent necrotizing lymphadenitis (may assoc w/ SLE, MAS, TB); Sx included fever, flu-Sxs, Wt loss, night sweats, Hi CRP/LFTs, lymphopenia, uncommon arthritis, organomegaly https://t.co/LpEOgbcfpP
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of Herpes zoster from upadacitinib RCTs: UPA > ADA > ADA+MTX > MTX. 5306 RA pts, HZ/100 Pt-Yrs was 0.8 MTX mono; 1.1 ADA+MTX; 3.0 UPA 15 mg and 5.3 UPA 30 mg. 71% of UP HZ cases involved a single dermatome. Higher risk w/ prior HZ & Asians https://t.co/0QUvXmFrJ3
Links:
Dr. John Cush RheumNow ( View Tweet)
Are You a High or Low Glucocorticoid Prescriber?
https://t.co/QbJzlrVMiV https://t.co/dZgJPKjisx
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.
Read more on #RheumNow
https://t.co/Q422Sl5Csj
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download.
https://t.co/Y6Pqko1tYm https://t.co/2IvMIfPBkr
Links:
Dr. John Cush RheumNow ( View Tweet)
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/1pnXJkoCOn
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it…
Still’s Disease Following COVID-19 Vaccination
Read more on #RheumNow
https://t.co/23R41Pydve https://t.co/a44cYIkc98
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hepatitis B Reactivation with Rituximab and Abatacept
A serologic study of rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without HBsAb positivity.
https://t.co/l1qCrWCyZd
#RheumNow https://t.co/EUoWt9xGdB
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it:
FDA Approves Avacopan for ANCA-Associated Vasculitis
https://t.co/L7UwhYBaVY
#RheumNow https://t.co/HypjLMLwjU
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Triple DMARD Rx - MSH vs MLH (Lef). 136 active #RA pts given OL MTX/SSZ/HCQ vs MTX/HCQ/LEF. Equal efficacy (EULAR-Good) was seen at wk 12 (54% vs 59%) and wk 24 (65% vs 62%) - hence LEF substitution was noninferior. https://t.co/F5CGj0w7Bh https://t.co/OuDMgNIKTA
Links:
Dr. John Cush RheumNow ( View Tweet)
For best practices in managing the Delta wave, the US would have done well to consult Puerto Rico
US 26 cases/100,000 people, 19/100K hospitalized 57% vaccinated
PR 3 cases/100,000 people, 3/100K hospitalized, 68% vaccinated https://t.co/kqlXBlmYpu
Eric Topol EricTopol ( View Tweet)
This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍 https://t.co/fYB0IzE7kY
Emilio Martin Mola emartinmola ( View Tweet)
